VTGN

Vistagen Therapeutics INC

-$1.6M

Net Activity

Institutions Holding

57

Popularity Rank

#5675

Avg Weight

0.01%

Total Value

$8.4M

Ownership Trend

57 institutions currently hold VTGN, with 26 net buyers and 26 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Neutral

Based on recent trading activity

Net Selling Institutions

26

Net Buying Institutions

26

Key Holders

View all 57 holding institutions

Quarterly Activity

Recent Activity

+$3.0M

Total Buy Value

$4.4M

Total Sell Value

New buy12
Trim12
Add14
Sold out14

26

Net Buyers

26

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

1

Filings (14d)

Data as of 2026-06-30

View all Form 8-K filings

FAQ

Who are the top institutional investors holding VISTAGEN THERAPEUTICS INC (VTGN)?
Major stakeholders currently include Orbimed Advisors LLC ($1.7M), TCG Crossover Management, LLC ($1.5M), Vanguard Capital Management LLC ($900.4K). Based on the latest 13F filings, there are a total of 57 tracked investment funds and institutions maintaining positions in VTGN.
What is the overall institutional sentiment toward VTGN recently?
Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $1.6M, driven by 26 managers accumulating shares while 26 reduced their exposure.
Which institutions have been selling or reducing their VTGN positions?
In the latest period, 12 funds trimmed their holdings, and 14 managers completely exited their positions. The aggregate reported sell value was $4.4M.
Are there any notable investors adding VTGN to their portfolios?
Yes, buying activity remains notable. 12 institutions opened new positions in {ticker}, and 14 existing holders added to their shares. The total reported buy value for the quarter amounted to $3.0M.

Related Stocks